South Korea · Delayed Price · Currency is KRW Kukje Pharma Statistics
Total Valuation
Kukje Pharma has a market cap or net worth of KRW 88.68 billion. The enterprise value is 105.63 billion.
| Market Cap | 88.68B |
| Enterprise Value | 105.63B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kukje Pharma has 20.36 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 20.36M |
| Shares Outstanding | 20.36M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.70% |
| Owned by Institutions (%) | 6.23% |
| Float | 12.71M |
Valuation Ratios
The trailing PE ratio is 13.91.
| PE Ratio | 13.91 |
| Forward PE | n/a |
| PS Ratio | 0.53 |
| PB Ratio | 0.95 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 13.48 |
| P/OCF Ratio | 10.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.10, with an EV/FCF ratio of 16.06.
| EV / Earnings | 16.57 |
| EV / Sales | 0.63 |
| EV / EBITDA | 9.10 |
| EV / EBIT | 12.53 |
| EV / FCF | 16.06 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.26 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 4.48 |
| Interest Coverage | 8.26 |
Financial Efficiency
Return on equity (ROE) is 7.00% and return on invested capital (ROIC) is 4.41%.
| Return on Equity (ROE) | 7.00% |
| Return on Assets (ROA) | 3.18% |
| Return on Invested Capital (ROIC) | 4.41% |
| Return on Capital Employed (ROCE) | 5.88% |
| Revenue Per Employee | 676.66M |
| Profits Per Employee | 25.70M |
| Employee Count | 248 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 3.48 |
Taxes
In the past 12 months, Kukje Pharma has paid 1.62 billion in taxes.
| Income Tax | 1.62B |
| Effective Tax Rate | 20.24% |
Stock Price Statistics
The stock price has decreased by -19.10% in the last 52 weeks. The beta is 0.54, so Kukje Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -19.10% |
| 50-Day Moving Average | 4,652.90 |
| 200-Day Moving Average | 4,811.73 |
| Relative Strength Index (RSI) | 29.10 |
| Average Volume (20 Days) | 92,813 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kukje Pharma had revenue of KRW 167.81 billion and earned 6.37 billion in profits. Earnings per share was 313.02.
| Revenue | 167.81B |
| Gross Profit | 89.98B |
| Operating Income | 8.43B |
| Pretax Income | 7.99B |
| Net Income | 6.37B |
| EBITDA | 11.60B |
| EBIT | 8.43B |
| Earnings Per Share (EPS) | 313.02 |
Balance Sheet
The company has 12.54 billion in cash and 29.48 billion in debt, giving a net cash position of -16.94 billion or -831.89 per share.
| Cash & Cash Equivalents | 12.54B |
| Total Debt | 29.48B |
| Net Cash | -16.94B |
| Net Cash Per Share | -831.89 |
| Equity (Book Value) | 93.41B |
| Book Value Per Share | 4,586.53 |
| Working Capital | 35.76B |
Cash Flow
In the last 12 months, operating cash flow was 8.67 billion and capital expenditures -2.09 billion, giving a free cash flow of 6.58 billion.
| Operating Cash Flow | 8.67B |
| Capital Expenditures | -2.09B |
| Free Cash Flow | 6.58B |
| FCF Per Share | 323.11 |
Margins
Gross margin is 53.62%, with operating and profit margins of 5.03% and 3.80%.
| Gross Margin | 53.62% |
| Operating Margin | 5.03% |
| Pretax Margin | 4.76% |
| Profit Margin | 3.80% |
| EBITDA Margin | 6.91% |
| EBIT Margin | 5.03% |
| FCF Margin | 3.92% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.69%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.69% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 4 |
| Payout Ratio | 9.58% |
| Buyback Yield | -0.28% |
| Shareholder Yield | 0.41% |
| Earnings Yield | 7.19% |
| FCF Yield | 7.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Mar 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Kukje Pharma has an Altman Z-Score of 2.28 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.28 |
| Piotroski F-Score | 7 |